Becton Dickinson (NYSE: BDX) reported Q2 EPS of $2.59, $0.01 better than the analyst estimate of $2.58. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.24 billion.

"Through the second quarter we have delivered solid revenue growth and operating performance," said Vincent A. Forlenza, chairman and CEO. \"Our revised fiscal year 2019 outlook reflects recent, near-term regulatory and market pressures related to paclitaxel-coated devices and foreign currency, which will affect our EPS guidance range. We remain confident that our business is strong, fundamentals are in-tact, and we will continue to deliver value to our shareholders and customers around the world."

GUIDANCE:

Becton Dickinson sees FY2019 EPS of $11.65-$11.75, versus the consensus of $12.07.

As reported, the company expects full fiscal year 2019 revenues to increase 8.0 to 9.0 percent, compared to 8.5 to 9.5 percent previously communicated, due to the estimated additional negative impact from foreign currency. The company continues to estimate full fiscal year 2019 revenues will increase 5.0 to 6.0 percent on a comparable, currency-neutral basis.

The company expects adjusted diluted earnings per share to be between $11.65 and $11.75, resulting in growth of approximately 12.0 percent on a currency-neutral basis. This is a decrease from previously issued guidance of approximately 13.0 to 14.0 percent growth, and is due to recent regulatory and market pressures related to paclitaxel-coated devices. Including the estimated additional unfavorable impact of foreign currency, adjusted diluted earnings per share are expected to grow approximately 6.0 to 7.0 percent over fiscal 2018 adjusted diluted earnings per share of $11.01.

For earnings history and earnings-related data on Becton Dickinson (BDX) click here.